Innovative Medicines Initiative launches IMI 2 – Call 6

The Innovative Medicines Initiative (IMI) has launched a new Call for proposals, giving researchers from
diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way
for the development of the medicines of the future.

IMI encourages small and medium-sized enterprises (SMEs), mid-sized companies, patients’ organisations,
regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and
apply to participate in the new IMI projects.

IMI 2 – Call 6 includes the following topics:
Development of Quantitative System Toxicology (QST) approaches to improve the understanding of the safety of new medicines

Establishing impact of respiratory syncytial virus (RSV) infection, resultant disease and public health approach to
reducing the consequences

Topics under the new Big Data for Better Outcomes programme:

Real World Outcomes Across the Alzheimer’s disease (AD) Spectrum (ROADS) to Better Care
Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with haematologic malignancies.

Find project partners

IMI’s Partner Search Tool - - allows people interested in applying for IMI funding to search for potential project partners. It has been updated with the IMI 2 – Call 6 topics.

Deadline for submitting short proposals: Tuesday 12 January 2016